You are here: Industry Insights > Tumor

News List

Pre-Op Treatment May Be Advance Against Deadly Liver Cancers drugs.com
January 28, 2022
When delivering a liver cancer diagnosis, Dr. Thomas Marron pulls no punches: "Liver cancer is one of the deadliest cancers," he tells patients.
FDA Accepts Rakuten Medical’s IND Application for Oncology Candidate contractpharma
December 17, 2021
Will begin clinical studies of RM-1995 photoimmunotherapy in advanced head and neck cancer.
NEUVOGEN Appoints Mark W. Frohlich to its Board of Directors and Scientific Advisory Board firstwordpharma
August 24, 2021
NEUVOGEN, an immunoncology company, is pleased to announce the appointment of Dr. Mark W. Frohlich, MD to its Board of Directors and Scientific Advisory Board ("SAB") effective August 23, 2021.
Sapience Therapeutics Enters Into Collaboration with National Cancer Institute (NCI) to Study ST101 Response in Specialized Tumor Models firstwordpharma
May 31, 2021
Sapience Therapeutics announced today that it has entered into a Collaboration Agreement with the National Cancer Institute of the National Institutes of Health to investigate the activity of its lead clinical program
Cabozantinib reduces tumour burden in Phase II neurofibromatosis trial europeanpharmaceuticalreview
January 18, 2021
Forty percent of neurofibromatosis type 1 patients enrolled in the trial had a >20 percent reduction in tumour burden with cabozantinib.
New Resource for Survivors from NCCN Helps Guide Life After Cancer Diagnosis and Treatment prnasia
January 06, 2021
The National Comprehensive Cancer Network® (NCCN®) announced the publication of new, free informational resources on health and wellness for cancer survivors.
Singlera Genomics raises $150 million in Series B financing to promote the development and commercialization of early cancer screening products prnasia
December 16, 2020
Singlera Genomics Inc. announced that it raised $150 million in Series B financing. This round of financing was led by the CICC Kai Tak Innovative Biomedicine Fund, and co-led by Detong Capital and Furong Investment.
Pionyr Immunotherapeutics Initiates Phase 1 Clinical Study of PY314 americanpharmaceuticalreview
December 04, 2020
Pionyr Immunotherapeutics announced the initiation of a Phase 1 clinical study investigating PY314 in patients with solid tumors.
Cannabics Concludes Pre-Clinical Study on Human Biopsies americanpharmaceuticalreview
November 19, 2020
Cannabics Pharmaceuticals has completed a pre-clinical study using its proprietary and novel RCC-33 formulation on human biopsies, obtained under a Helsinki Committee approved protocol.
I-Mab Reports Phase 1 Clinical Trial Data of Highly Differentiated Anti-CD47 Monoclonal Antibody Lemzoparlimab at the 2020 SITC Annual Meeting prnasia
November 10, 2020
I-Mab announced initial results from its U.S. phase 1 clinical trial (NCT03934814) evaluating lemzoparlimab (also known as TJC4) for the treatment of relapsed or refractory solid tumors and lymphoma.

Previous page 1 2 3 4 5 6 7 Next page